Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Tazeen Ahmad - Bank of America David Lebowitz - Citibank Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Marc Frahm - TD Cowen Kelly Shi - Jefferies Brian Abrams - RBC Capital Markets Jay Olson - Oppenheimer Matt Phipps - William Blair Andrew Berens - Leerink Partners Andy Chen - Wolfe Research Salim Sayed - Mizuho Evan Seigerman - BMO Capital Markets Srikripa Devarakonda - Truist Securities Operator Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode.
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Incyte (INCY) Q4 Earnings Miss Estimates
Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago.
Incyte reports quarterly sales above estimates on strong demand for key drugs
Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Incyte (INCY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
Has Incyte (INCY) Outpaced Other Medical Stocks This Year?
Here is how Incyte (INCY) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.
Incyte: Multiple Drug Launches Bode Well For Future Growth
Incyte's robust growth, led by JAKAFI and OPZELURA, is set to increase with new product launches of MONJUVI, ZYNZY, and NIKTIMVO in 2025. Analysts expect Incyte's revenues to grow by ~10% annually until JAKAFI's patent expiration in 2028, however, recent sales growth momentum and new product launches seem poised to outperform expectations. The company aims to launch 10 high-impact products by 2030, with promising pipeline assets like INCB123667 and povorcitinib showing promising clinical activity.
INCY vs. VRTX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- INCY
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.
